SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming utilities, P2E Telegram games, and weekly contests to reward holders. Discussions highlight a potential token burn event at 2500 watchers, alongside the coin's resilience as a Solana survivor meme coin. Community members emphasize active development and ongoing efforts to engage and reward the "Spare Change Army".

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users promote the coin and its association with cannabis culture. The community emphasizes the coin's cultural significance, steady growth, and resilience. Some users are also speculating about potential upcoming catalysts such as a CMC listing.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors discuss the company's potential as an AI acquisition target, particularly after recent activity in the data labeling space. Community members are analyzing INOD's recruitment strategies, financial positioning, and technical indicators, interpreting them as signs of a potential takeover or significant new contracts. Bullish sentiment prevails, with focus shifting towards potential short squeezes and price targets.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst community disagreement on its potential, with some expressing frustration over its price action relative to Bitcoin's surge and other altcoins. Discussions revolve around potential catalysts, including partnerships and broader market trends, while others dismiss the project as a lost cause, pointing to its ranking decline. The community is split between those who remain optimistic, accumulating more JASMY, and those who are highly critical, predicting further decline.

GME Ethereum

GME Ethereum is trending as the community anticipates a potential "god candle" and a tweet from Roaring Kitty, sparking excitement. Conversations revolve around potential catalysts and the overall bullish sentiment surrounding the coin. Some community members highlight locked liquidity and a "savage" team as reasons for optimism, while others suggest that it is a scam.

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARKG is gaining attention as investors discuss potential breakout patterns and compare its performance to other ARK funds, with some expressing frustration over its historical returns. Community members are actively debating entry points and speculating on future catalysts, particularly the impact of AI on genomic advancements. Despite mixed sentiment regarding management, there's anticipation for a potential sector-wide upswing and the impact of future rate cuts.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex).  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

USDT is trending as community members discuss its relationship with Rumble, including Tether's stake in the company and the upcoming integration of USDT payments in the Rumble Wallet. There is also discussion around Tether's role in the broader crypto market, including minting activities and its dominance among stablecoins. The potential impact of new regulations and competition from other stablecoins are also being considered.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

CORZ is trending as investors discuss the pending acquisition by CRWV, with many believing the deal undervalues CORZ, especially given CRWV's growing AI business and recent insider selling. Shareholders are weighing the benefits of AI exposure against concerns about management decisions and the exchange ratio, while also considering voting against the deal to push for a higher premium or explore alternative offers. The community is closely monitoring the merger vote and speculating on potential renegotiations.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors celebrate the stock's recent gains, with many long-term holders expressing excitement about breaking past the $40 mark and some anticipating a Nasdaq relisting. Community members are also discussing the company's expansion in China and the U.S., viewing it as a potential challenger to Starbucks, especially as Luckin innovates with new products and offers competitive pricing.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is trending following a strong earnings report driven by Hollister's performance, though investors are weighing this against a lowered profit outlook due to tariffs; the community is analyzing the potential for continued growth amid economic headwinds and brand relevance, with some pointing to attractive valuations and buyback programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Equity

5 ETFs That Beat the Market in the First Half of 2025

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

Shares of Mind Medicine Inc. climbed over 2% on Tuesday afternoon, on track to break a two-session losing streak, as Evercore ISI initiated coverage with an&nbsp;‘Outperform’&nbsp;rating and a bullish $23 price target, suggesting over 200% upside from current levels.Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset MM120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).&nbsp;The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.Last month, Chardan initiated coverage with a&nbsp;‘Buy’ rating and a $20 price target, citing MM120’s potential to deliver over $1 billion in peak sales by 2026, assuming positive trial data and a strong commercial launch.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_Jan_28_9a6374b37a.png" alt="MNMD sentiment and message volume Jan 28.png" width="1318" height="324"><figcaption>MNMD sentiment and message volume Jan 28 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Mind Medicine turned ‘bullish’ from ‘neutral,’ with increased message volume reflecting optimism.&nbsp;<stembedurl>https://stocktwits.com/EMT6/message/601825856</stembedurl><stembedurl>https://stocktwits.com/MichaelNaussCMT/message/601770767</stembedurl>Analysts expect sentiment to improve further in 2025, as the company nears key catalysts, including pivotal trial updates.Mind Medicine recently launched a Phase 3 trial of MM120 in GAD and expanded its intellectual property protection through 2041 by obtaining a patent for an orally disintegrating tablet (ODT) formulation.&nbsp;The Nasdaq Biotechnology Index (NBI) added the stock in December, which analysts noted could bolster institutional interest.The company ended the third quarter of 2024 with $295.28 million in cash and $24.31 million in debt.&nbsp;<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine</a> recently said it raised $250 million last year through two equity financings.The small-cap biotech’s stock has returned about 90% over the past 12 months, though its short interest stands at 13.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s lead asset MM120 targets generalized anxiety disorder (GAD) and major depressive disorder (MDD). | Image source: Getty Images

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 

Shares of Cybin, Inc. (<a class="mention" data-mention="$CYBN" data-symbol-id="CYBN" href="https://stocktwits.com/symbol/CYBN" target="_blank">$CYBN</a>) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” 12-month efficacy data from a Phase 2 study of the biopharma’s major depressive disorder (MDD) treatment.The company reported that two 16 mg doses of CYB003, a proprietary deuterated psilocin program, spaced three weeks apart, showed “consistent, robust, and sustained” treatment benefits through the 12-month follow-up.&nbsp;This data supports the potential of CYB003 as an adjunctive treatment for MDD patients who have not achieved remission with first-line antidepressants, Cybin said.The U.S. Food and Drug Administration (FDA) recently granted CYB003 Breakthrough Therapy Designation, accelerating its review process.Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.&nbsp;“We are quite possibly witnessing a watershed moment in mental health care treatment paradigms and practices,” he said.Drysdale emphasized that current treatments, such as esketamine and electroconvulsive therapy (ECT), require up to 36 outpatient visits per treatment cycle, creating a significant burden on both patients and healthcare facilities.&nbsp;In contrast, CYB003’s two-dose treatment regimen could offer a more patient-friendly, long-lasting alternative.On Stocktwits, retail sentiment for CYBN turned ‘extremely bullish,’ with users expressing optimism about the future of the company and its potential impact on mental health care.&nbsp;Some users pointed to potential regulatory support under a Trump administration, suggesting that prominent figures like Robert F. Kennedy Jr. as HHS Secretary could expedite FDA approval for CYB003.<stembedurl>https://stocktwits.com/PsychedStocks/message/592985335</stembedurl>Another hoped that the stock would double to $25 soon.&nbsp;<stembedurl>https://stocktwits.com/DJTHollaAtMe/message/593002464</stembedurl>Analyst firms remain optimistic, even as Canaccord maintained a ‘Buy’ rating while lowering its price target to $86 from $96 last week.&nbsp;Alliance Global Partners, meanwhile, raised its target to $25 from $6, reflecting the potential upside based on CYB003’s progress and ongoing Phase 3 trials.Still, Cybin’s stock has seen a 19% decline year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.comRead next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lbrt-stock-rises-as-ceo-to-join-trump-cabinet/cJ4vdwSRQe">Liberty Energy Stock Pops Following CEO’s Nomination To Trump’s Cabinet: Retail Buzz Grows</a>

The U.S. Food and Drug Administration (FDA) recently granted Cybin's CYB003 Breakthrough Therapy Designation, accelerating its review process.

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish

Cybin's CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

AdvisorShares Announces Reverse Split of ETF

AdvisorShares Announces Reverse Split of ETF AdvisorShares Announces Reverse Split of ETF PR Newswire BETHESDA, Md., Aug. 30, 2024 BETHESDA, Md., Aug. 30, 2024 /PRNewswire/ -- AdvisorShares, a...

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.Earlier this month, FSD Pharma underwent a significant transformation. The company consolidated its shares to increase the price to $18 per share and meet Nasdaq listing requirements. It was also rebranded as Quantum BioPharma (QNTM).Quantum also conducted a private placement, offering new shares to existing Class A shareholders. This move aimed to restore voting rights to the Class A shares, aligning them closer to their pre-2018 public offering levels.Adding to the recent buzz is the company's investment in Celly Nutrition, specifically their "unbuzzd" product — a drink designed to accelerate metabolism and aid in faster recovery from alcohol consumption.It's set to launch as powder packs on Amazon later this month, with ready-to-drink versions planned for later in the year.To support the release of unbuzzd, FSD Pharma launched a round of financing via the sale of 6,833,332 shares of HUGE stock at $203,469. The company has the option to sell more shares to raise additional funds.Several retail investors on Stocktwits were talking about unbuzzd, with some users sharing screenshots of the product available for purchase on Amazon on Monday.<stembedurl>https://stocktwits.com/ImYourDaddyy/message/584111359</stembedurl>This coincided with a surge in trading volume of QNTM, exceeding double its daily average of about 24,000 shares.However, the Amazon product link for unbuzzd on its official site currently leads to a "not found" page.<stembedurl>https://stocktwits.com/singa_stock/message/584171177</stembedurl>Currently, retail sentiment on Stocktwits for QNTM has turned 'neutral' (45/100) from 'bearish' a week ago.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/QNTM"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QNTM_sentiment_and_message_volume_Aug_26_2ce78f9e9d.png" alt="QNTM sentiment and message volume Aug 26.png" width="1310" height="316"></a><figcaption>QNTM sentiment and message volume Aug 26</figcaption></figure>&nbsp;Read Next: <a href="https://stkt.co/4CnRWSRT">Xpeng Stock Jumps, Retail Turns ‘Bullish’ After CEO Boosts Stake</a>&nbsp;&nbsp;&nbsp;&nbsp;

Quantum BioPharma-backed Celly Nutrition's Unbuzzd

Quantum Biopharma Stock (QNTM) Sees Retail Following Skyrocket Over 2,500% In A Week

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.

QNTM Sees Retail Following Skyrocket Over 2,500% In A Week

The heightened focus comes after a series of strategic moves by the company, including rebranding, share consolidation, and an upcoming product launch.  


Advisorshares Trust - AdvisorShares Psychedelics ETF

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$19.89
Prev Close	$19.65
Open	$19.85
Dividend Yield	N/A
50-Day Moving Average	$17.26
Beta	N/A
Avg. Volume	15,295.24
PE Ratio	N/A

52-Week High	$20.01
52-Week Low	$7.14
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PSIL
AdvisorShares Psychedelics ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PSIL News

PSIL AdvisorShares Psychedelics ETF